There's a good chance you have fatty liver disease and don't know it. It affects roughly 30% of adults globally, most of whom are never diagnosed because it rarely causes symptoms until the damage is advanced. If you have obesity, insulin resistance, or type 2 diabetes — the same conditions that lead many people to GLP-1 medications — your risk is substantially higher.
In 2025, semaglutide received FDA approval for metabolic dysfunction-associated steatohepatitis (MASH) — what used to be called NASH. This makes it only the second medication ever approved specifically for this condition, and the first GLP-1 receptor agonist. It's a significant development for the millions of people whose livers are quietly accumulating damage.
What is MASH (and why did the name change)?
The liver disease formerly called NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis) was renamed in 2023 to better reflect its metabolic origins:
MASLD (metabolic dysfunction-associated steatotic liver disease) — fat accumulation in the liver. This is the broader condition, affecting roughly 30% of adults. Many people with MASLD have no symptoms and no significant liver damage.
MASH (metabolic dysfunction-associated steatohepatitis) — the more severe form where fat accumulation has triggered inflammation and liver cell damage (hepatitis). This is the dangerous progression. MASH can lead to fibrosis (scarring), cirrhosis, liver failure, and liver cancer.
The "non-alcoholic" label was dropped because it was stigmatising and inaccurate — many people with the condition do drink alcohol, and the metabolic drivers are the same regardless. The new terminology focuses on what actually causes the disease: metabolic dysfunction.
Why GLP-1 medications help the liver
The mechanisms are multiple and synergistic:
Weight loss: Reducing body weight by 10% or more can resolve MASH in a significant proportion of patients. GLP-1 medications routinely achieve this level of weight loss.
Insulin resistance improvement: Insulin resistance drives fat accumulation in the liver. GLP-1 medications improve insulin sensitivity, reducing the metabolic conditions that cause hepatic steatosis.
Direct anti-inflammatory effects: GLP-1 receptors are present in the liver, and their activation appears to reduce hepatic inflammation and oxidative stress independent of weight loss. This is an area of active research, but the evidence suggests GLP-1 medications have liver-specific benefits beyond what weight loss alone would predict.
Reduction in liver fat content: Multiple studies have shown dramatic reductions in liver fat — measured by MRI — in patients treated with GLP-1 medications.
The semaglutide MASH data
The approval was based on the phase 3 trials evaluating semaglutide in patients with biopsy-confirmed MASH and significant liver fibrosis. The results showed that semaglutide achieved MASH resolution (disappearance of liver inflammation without worsening fibrosis) in a significantly higher proportion of patients compared to placebo.
These results build on earlier phase 2 data that showed semaglutide resolved MASH in approximately 59% of treated patients versus 17% with placebo — an impressive treatment effect for a condition that previously had almost no effective pharmacological options (Newsome et al., 2021).
The approval is specifically for semaglutide — not tirzepatide (though tirzepatide is being studied for MASH as well, and early data is promising). For people with both obesity and MASH, this gives semaglutide a unique advantage in the treatment landscape.
How to know if you have fatty liver disease
This is the challenge. Most people with MASLD or early MASH have no symptoms. The condition is typically discovered incidentally — through elevated liver enzymes on routine blood work, or through imaging done for another reason.
Risk factors that should prompt screening:
- Obesity (BMI ≥30)
- Type 2 diabetes or prediabetes
- Metabolic syndrome (high blood pressure, high triglycerides, low HDL cholesterol, large waist circumference)
- Insulin resistance
- Family history of liver disease
Screening methods:
- Blood tests: liver enzymes (ALT, AST), the FIB-4 index (a non-invasive fibrosis scoring system using routine blood tests)
- Ultrasound: can detect fat accumulation but isn't great at detecting inflammation
- FibroScan (transient elastography): non-invasive assessment of liver stiffness (fibrosis) and fat content
- MRI-PDFF: the gold standard for measuring liver fat content
- Liver biopsy: the definitive diagnostic test, but invasive and typically reserved for uncertain cases
If you're starting or already taking a GLP-1 medication for weight loss or diabetes, it's worth asking your doctor about liver screening. You may already have lab work that provides clues.
What this means for your GLP-1 treatment
If you have both obesity and fatty liver disease, semaglutide's MASH indication adds another compelling reason to consider it specifically.
Already on semaglutide (Ozempic or Wegovy)? You're already getting the liver benefit. Your doctor may want to monitor liver enzymes and potentially order imaging to track improvement. No medication change is needed.
On tirzepatide (Mounjaro or Zepbound)? Tirzepatide also improves liver fat and inflammation, though it doesn't have the specific MASH approval yet. Trials are underway. If liver disease is a primary concern, discuss with your doctor whether the semaglutide indication matters for your specific situation.
Not on any GLP-1 medication? If you have diagnosed MASH with fibrosis, semaglutide's FDA approval means you now have a medication specifically indicated for your liver condition that also addresses weight and metabolic health. This can change the insurance conversation — a liver disease indication may open coverage pathways that weight loss alone doesn't.
The broader picture
Semaglutide's MASH approval is part of a larger trend: GLP-1 medications evolving from "weight loss drugs" into multi-system metabolic therapies. The same medication class now has approved indications spanning obesity, type 2 diabetes, cardiovascular risk reduction, chronic kidney disease, sleep apnoea (tirzepatide), and now liver disease.
For the estimated 15-20 million Americans with MASH — most of whom are undiagnosed — this represents a treatment option that didn't exist two years ago for a condition that was on a trajectory toward liver failure and transplant. The fact that the medication simultaneously addresses the weight, metabolic, and cardiovascular conditions that typically accompany MASH makes it uniquely suited to this patient population.
If you have risk factors for fatty liver disease, get screened. If you have MASH, talk to your hepatologist or gastroenterologist about semaglutide. And if you're already on a GLP-1 medication for another reason, know that your liver is likely benefiting too.
Key Studies & References
-
Newsome et al. (2021) — Phase 2 trial of semaglutide in biopsy-confirmed NASH showing 59% MASH resolution with semaglutide versus 17% with placebo, establishing the evidence base for the class's liver effects. Read the full study
-
Lincoff et al. (2023) — The SELECT trial demonstrating semaglutide's cardiovascular benefits, relevant because MASH patients have significantly elevated cardiovascular risk. Read the full study
-
Wilding et al. (2021) — The STEP 1 trial showing ~15% weight loss with semaglutide 2.4mg — the level of weight reduction associated with significant MASH improvement. Read the full study